CIK细胞治疗消化系统肿瘤的效果
发布时间:2018-06-23 来源: 感悟爱情 点击:
[摘要]目的 探讨CIK细胞治疗消化系统肿瘤的效果。方法 选取2012年1月1日~2014年2月25日我院收治的消化系统肿瘤患者100例为研究对象,按照消化系统肿瘤患者治疗措施的差异分为对照组、实验组,每组50例。其中对照组实施姑息减症治疗,实验组则实施CIK细胞治疗,对比两组消化系统肿瘤患者治疗结果的差异性。结果 实验组患者的CD3+与CD3+CD8+的水平显著高于对照组(P<0.05);两组患者的OS与PFS比较,差异无统计学意义(P>0.05)。实验组患者的生活质量显著优于对照组(P<0.05);实验组患者的肿瘤标志物(CA724、CA199)显著低于对照组(P<0.05),两组腹腔积液水平比较,差异无统计学意义(P>0.05)。结论 消化系统肿瘤患者接受CIK细胞治疗,可以对患者的免疫力、生活水平以及肿瘤标志物进行改善,但是在生存期、腹腔积液等方面无显著的改善效果。
[关键词]消化系统肿瘤;CIK细胞;生物治疗
[中图分类号] R735 [文献标识码] A [文章编号] 1674-4721(2018)2(b)-0086-03
CIK cells in the treatment of digestive system tumors
SUN Jie1 WANG Xing1 WANG Cui-fang1 ZHANG Chun-yang2
1.Department of Pathology,Affiliated Central Hospital of Shenyang Medical University,Liaoning Province,Shenyang 110024,China;2.Department of Emergency,Affiliated Central Hospital of Shenyang Medical University,Liaoning Province,Shenyang 110024,China
[Abstract]Objective To investigate the therapeutic effect of cik cells on digestive system tumors.Methods From January 1,2012 to February 25,2014,100 cases of digestive system tumor patients in our hospital were selected as the research objects,according to the differences in treatment measures of digestive system tumor patients were divided into control group,experimental group,50 cases in each group.The control group was treated with palliative treatment,while the experimental group was treated with CIK cells.The difference of treatment results between the two groups were compared.Results The levels of CD3+ and CD3+CD8+ in the experimental group were significantly higher than those in the control group (P<0.05).There was no significant difference between the two groups in OS and PFS (P>0.05).The quality of life of the experimental group was significantly better than that of the control group (P<0.05).The tumor markers (CA 724,CA199) in the experimental group were significantly lower than those in the control group (P<0.05).There was no significant difference in the level of peritoneal effusion between the two groups (P>0.05).Conclusion Patients with digestive system tumors receiving CIK cell therapy can improve their immunity,living standards and tumor markers,but there is no significant improvement in survival time,peritoneal effusion and other aspects.
[Key words]Digestive system tumors;CIK cells;Biotherapy
消化系統肿瘤是恶性肿瘤之一,其具有较高的死亡率和发生率,其死亡率占据恶性肿瘤的首位[1]。随着靶向治疗、化疗、放疗、手术治疗等综合治疗措施的应用,使得消化道肿瘤患者的生存率得到了一定程度的提高。若消化系统肿瘤患者经综合治疗后无效或处于疾病的晚期,则可为患者实施姑息治疗[2-3]。随着医疗技术水平的不断发展,使得分子免疫技术和分子生物技术在不断的发展,其中肿瘤生物治疗具有特异性杀伤的效果,且毒副作用小,已经逐渐被应用于恶性肿瘤的治疗中[4-5]。CIK(细胞因子诱导杀伤细胞)生物治疗已经在临床中被广泛的应用。本文主要对消化系统肿瘤患者接受CIK细胞治疗的价值作分析,现报道如下。
热点文章阅读